Abstract
A small proportion of patients with amyotrophic lateral sclerosis (ALS) survive more than 5 years. The frequency of 5-year or longer survival with ALS in a USA population is unknown but may provide a baseline for studies that employ survival as a primary endpoint of analysis. All persons diagnosed as having ALS in Olmsted County between 1925 and 2004 were studied for demographic and clinical features. Longer-term survivors were defined as patients who lived 5 years or longer, tracheostomy-free, following symptomatic onset. 94 patients (mean survival from symptomatic onset 2.95 years (95% CI 2.54 to 3.35), mean survival from diagnosis 1.89 years (95% CI 1.54 to 2.24)) were diagnosed as having ALS. Five-year or longer survivors accounted for 14% of the population of patients (95% CI 7.9% to 22.8%). The frequency of 5 year or longer survivors did not change over time. The mean survival of these individuals was 7.04 years (95% CI 6.14 to 7.94 years; range 5.11-9.35 years). They had a significantly longer mean time to diagnosis (1.77 years, 95% CI 0.95 to 2.58 years) as compared with survivors of less than 5 years (0.94 years, 95% CI 0.75 to 1.13 years) (p=0.02) but could not be reliably identified at the time of diagnosis by age, s...Continue Reading
References
Oct 1, 1978·Archives of Neurology·A D Rosen
Apr 1, 1990·Neurology·P B ChristensenN B Jensen
Jul 1, 1994·Journal of the Neurological Sciences·B R Brooks
Aug 1, 1993·Journal of the Neurological Sciences·F NorrisH Norris
Jun 1, 1993·Journal of Neurology·A M ChancellorC P Warlow
Mar 20, 2001·Archives of Neurology·L P Rowland
Mar 12, 2003·Neurology·M A del AguilaG van Belle
Jun 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·M R TurnerA Al-Chalabi
Nov 21, 2007·Journal of the Neurological Sciences·Stefano ZoccolellaGiancarlo Logroscino
Mar 25, 2009·Neurology·L C WijesekeraP N Leigh
Nov 20, 2009·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Adriano ChiòUNKNOWN Eurals Consortium
Citations
Oct 24, 2012·Cancer Causes & Control : CCC·D Michal FreedmanMargaret A Tucker
Jul 5, 2013·Brain : a Journal of Neurology·Gaëlle BruneteauDaniel Hantaï
Mar 9, 2013·Rinshō shinkeigaku = Clinical neurology·Kentaro HayashiShiro Matsubara
Dec 25, 2015·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Matthew S DevineRobert D Henderson
Apr 25, 2015·Annals of Clinical and Translational Neurology·Gaëlle BruneteauDaniel Hantaï
Oct 16, 2015·European Journal of Epidemiology·Benoît MarinEttore Beghi
Jan 30, 2015·Acta Neurologica Scandinavica·Z GongD Zang
Jan 24, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neta ZachMelanie L Leitner
May 18, 2016·International Journal of Epidemiology·Benoît MarinEttore Beghi
Dec 17, 2016·Expert Review of Neurotherapeutics·P A McCombeR D Henderson
Jan 19, 2019·Journal of Anesthesia·Alan M HoeperToby N Weingarten
Feb 9, 2012·Disability and Rehabilitation. Assistive Technology·Michele VitaccaSimonetta Scalvini
Aug 27, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Christopher B BradyNeil W Kowall
Feb 26, 2014·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Hiroshi MitsumotoUNKNOWN ALS COSMOS Study Group
Dec 4, 2019·Journal of Cellular Physiology·Misagh RajabinejadAlireza Rezaiemanesh
Jun 23, 2020·Expert Review of Neurotherapeutics·Pamela A McCombeRobert D Henderson
Aug 5, 2020·BMC Medical Imaging·Ashwag R AlruwailiPamela A McCombe
Mar 12, 2021·Neuroscience Letters·Philippe-Pierre RobichaudPier Jr Morin
Oct 29, 2021·Muscle & Nerve·Mai YamakawaJeffrey Statland
Nov 25, 2021·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Elisa BianchiEttore Beghi